Statistics

Total Visits

Views
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months63

File Visits

Downloads
Casado et al. - 2015 - Switching to second‐generation tyrosine kinase inhibitor improves the response and outcome of frontl.pdf2

Select a period of time:

Number of views in the range

Views
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months25

Number of downloads in the range

Downloads
Casado et al. - 2015 - Switching to second‐generation tyrosine kinase inhibitor improves the response and outcome of frontl.pdf2

Views

Views
June 20252
July 20257
August 20256
September 20254
October 20252
November 20254
December 20250
Download CSV file
 untranslated
 untranslated

Number of downloads in the period of time

  • Downloads
  • June 2025
    0
  • July 2025
    0
  • August 2025
    1
  • September 2025
    1
  • October 2025
    0
  • November 2025
    0
  • December 2025
    0
  • Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil10
Argentina2
Germany1
Spain1
Singapore1
United States1
Venezuela1
South Africa1
 

Top countries by downloads

Downloads
United States1
 

Top cities views

Views
Alejandro Korn1
Ames1
Barbacena1
Brasília1
Caracas1
Dallas1
Fortaleza1
Itabira1
Lomas de Zamora1
Munich1
 

Top cities by downloads

Downloads